Influenza

Haemophilus influenzae Type f Epiglottitis in a 3-Year-Old Boy

SRIKANTH ARAVAPALLI, MD, and SHASHI SAHAI, MD

Dr Aravapali is a pediatric resident and Dr Sahai is a clinical educator and assistant professor at Children’s Hospital of Michigan in Detroit.

 

A 3-year-old previously healthy boy presented to the emergency department with a 1-day history of fever, drooling, difficulty swallowing, vomiting, and respiratory distress. Upon arrival, the patient was sick-appearing and was using tripod positioning; he also was tachycardic and tachypneic with labored mouth-breathing and had moderate pooling of oral secretions. He had completed all the immunization series for his age. Pertinent physical examination findings included enlarged anterior cervical lymph nodes bilaterally, neck in extended position, and suprasternal retractions with referred stertorous upper airway sounds.

Out of concern for airway compromise, the patient underwent elective intubation. At this time, a photograph of the epiglottis was taken (Figure). The patient was transferred to the pediatric intensive care unit (PICU) on a ventilator in stable condition.

Haemophilus influenzae

The patient remained intubated in the PICU for 2 days and was treated with ceftriaxone, vancomycin, and clindamycin. Vancomycin and clindamycin later were discontinued based on the availability of culture results. Direct laryngoscopy/bronchoscopy showed erythematous, inflamed, and swollen epiglottis, false vocal cords, and arytenoid cartilages without exudate. Blood culture testing was positive for Haemophilus influenzae type f.

The boy was discharged on a 7-day course of amoxicillin-clavulanate after having received parenteral antibiotics for 5 days.

blood agar plate

Blood agar plate culture of H influenzae. Courtesy CDC/W.A. Clark

EPIGLOTTITIS: AN OVERVIEW

The epiglottis is a leaf-shaped elastic cartilage with overlying loose connective tissue that arises from the posterior tongue base and covers the laryngeal inlet during swallowing. Acute inflammation of the epiglottis can quickly and easily spread to the attached aryepiglottic folds and the arytenoid soft tissues, causing a more generalized supraglottitis.

Epiglottitis often presents with fever, sore throat, dysphagia, drooling, stridor, toxic appearance, and restlessness. Children with epiglottitis often assume the tripod position—leaning forward while bracing the arms and extending the neck—to maximize airway size. Vocalization is quite painful, and the patient may speak with a muffled or hot potato voice. Epiglottitis is a medical emergency that can lead to the rapid onset of life-threatening airway obstruction.

In the United States, the first polysaccharide vaccine to protect against H influenzae type b (Hib) was introduced in 1985. The polysaccharide-protein conjugate Hib vaccine, which induces immunity at a younger age, was licensed in the United States in 1987. The widespread introduction of the Hib conjugate vaccine in 1988 dramatically changed the epidemiology of acute epiglottitis.1 The overall annual incidence of epiglottitis has fallen dramatically in the Hib vaccine era, from approximately 5 cases per 100,000 to 0.6 to 0.8 per 100,000.2,3

H influenzae is classified into capsulated and noncapsulated microbiologic groups. Noncapsulated strains are nontypeable. Capsulated strains are further classified into 6 serotypes, a through f, based on antigenically distinct polysaccharide capsules. In the prevaccination era, Hib was the most commonly observed serotype at 64.9%, while nontypeable H influenzae comprised 29.9% of all isolates.4 H influenzae type f was the second most common typeable strain.5 Of isolates in the vaccination era, 70.3% are nontypeable, 13.6% are type f, and 9.4% are type b. While a few studies have suggested an increase in invasive H influenzae disease from nontypeable strains, no evidence exists to suggest a substantial or sustained increase.6

During the prevaccination era, 84% of cases of epiglottitis were caused by Hib, with a mean age of incidence of 4.1 years.7 Since the widespread implementation of the protein conjugate Hib vaccine, there has been a 95% reduction in Hib-related disease.8 Hib was the reported causative organism in 32% of epiglottitis patients in a vaccine era study in Boston.9 The peak age of epiglottitis was 3 years in the prevaccination era, but with the introduction of the Hib vaccine, its occurrence has shifted significantly to older patients. In this case series, the mean age at presentation of epiglottitis shifted from 5.8 years in the period from 1992 to 1997, to 11.6 years in the period from 1998 to 2002.9 Incidence of epiglottitis in adults has increased significantly in the Hib vaccine era.10

Other infectious agents in the vaccination era associated with epiglottitis include non–type b H influenzae, group A streptococci, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Haemophilus parainfluenzae, and β-hemolytic streptococci (groups B, C, and F). Candidal and viral infections (herpes simplex type 1, varicella-zoster, and parainfluenza) also have been implicated, particularly in immunocompromised individuals. Acute epiglottitis has a significant male predominance, with 63% of children with it being boys.10

h infuenzae

Photomicrograph of H influenzae as seen using a Gram-stain technique. Courtesy CDC

DIAGNOSIS AND MANAGEMENT

With the reduction in the incidence of pediatric epiglottitis, it is important to be aware of other conditions with a similar presentation, such as upper airway foreign body, esophageal foreign body, anaphylactic reactions, tracheitis, and retropharyngeal infections.

When epiglottitis is suspected, measures to secure the airway are the primary focus of intervention. Humidified oxygen and racemic epinephrine may be administered until the airway has been secured. It is also recommended that all other diagnostic tests and the placement of intravenous lines be postponed until the airway is secured, because the danger of partial airway obstruction worsening to complete obstruction and respiratory arrest is greater in an upset, crying child. Airway visualization should be performed in a controlled setting with readiness for intubation, such as an operating room, in the presence of an otolaryngologist and anesthesiologists who can secure the airway emergently if needed.

It is reasonable to forgo intubation and closely monitor older children and adults without respiratory distress and with at least a 50% laryngeal lumen on flexible laryngoscopy. In patients who do not require intubation at the outset, rapid respiratory compromise may develop in a delayed manner, with the majority of delayed compromise occurring in the first 12 hours of treatment, requiring emergent airway intervention.10 In one series of patients with epiglottitis, 69% of children needed an artificial airway.10

The risk factors for airway compromise are respiratory difficulty, drooling, stridor, and H influenzae bacteremia. Elevated white blood cell counts are a frequent finding, but positive blood culture results are extremely variable. Blood culture positivity for H influenzae in patients with epiglottitis ranged from 60% to 96% in various studies.7,10 Lateral neck radiographs may demonstrate the classic thumb sign, indicating severe epiglottic edema.

Broad-spectrum antibiotic coverage, typically a third-generation cephalosporin, is used. In the series from Boston, either ampicillin-sulbactam or ceftriaxone was effective in the successful treatment of all patients.9

Corticosteroids are used to decrease mucosal edema of the epiglottis in approximately two-thirds of children,9,10 but one 18-year series of patients with epiglottitis found that corticosteroid use made no difference in the need for airway placement, the duration of intubation, the duration of intensive care stay, or the duration of hospitalization.10 The mean duration of intubation in patients with epiglottitis has been reported as ranging from 55 hours11 to 3.5 days.9 Among the complications associated with epiglottitis are respiratory arrest, epiglottic abscess, and deep neck space infection. Mortality has been reported as 2.9%.10

PREVENTION AND VACCINATION

Hib causes as many as 95% of serious invasive H influenzae infections, including blood infections, meningitis, epiglottitis, cellulitis, pneumonia, arthritis, osteomyelitis, and pericarditis. Children between the ages of 2 to 4 months and 2 to 3 years are most susceptible to these serious infections.

Vaccination is the best way to prevent and control Hib. A 4-dose schedule (at 2, 4, 6, and 12 to 15 months) is recommended for most Hib vaccines. Still, despite the dramatic decrease of Hib-related infections after the introduction of the vaccine, Hib can cause epiglottitis despite adequate vaccination.9 It is important to measure Hib antibody levels in such patients to help determine whether they did not produce any antibody (vaccine failure) or whether they produced anticapsular antibody that afforded inadequate protection to Hib.

Vaccine failure may result from inadequate handling and storage of vaccines, which can cause a loss of antigenic epitopes or uncoupling of conjugation, leading to poor immunogenicity.

Children who experience Hib disease despite vaccination and adequate antibody levels may have a defect in immunologic priming, leading to a qualitative defect in Hib-specific memory cells.12 Reduced affinity of the antipolysaccharide capsule antibodies leads to poor functional activity and hence disease susceptibility despite vaccination. Future vaccine development efforts may need to be directed at type f and nontypeable strains of H influenzae. n

REFERENCES:

1. Tanner K, Fitzsimmons G, Carrol ED, Flood TJ, Clark JE. Haemophilus influenzae epiglottitis as a cause of acute upper airway obstruction in children. BMJ. 2002;325(7372):1099-1100.

2. Frantz TD, Rasgon BM. Acute epiglottitis: changing epidemiologic patterns. Otolaryngol Head Neck Surg. 1993;109(3 pt 1):457-460.

3. Faden H. The dramatic change in the epidemiology of pediatric epiglottitis. Pediatr Emerg Care. 2006;22(6):443-444.

4. Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28(24):4073-4078.

5. Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM; Haemophilus influenzae Study Group. Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. Clin Infect Dis. 1996;22(6):
1069-1076.

6. MacNeil JR, Cohn AC, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease—United States, 1989–2008. Clin Infect Dis. 2011;53(12):1230-1236.

7. Faden HS. Treatment of Haemophilus influenzae type B epiglottitis. Pediatrics. 1979;63(3):
402-407.

8. Wenger JD. Epidemiology of Haemophilus influenzae type B disease and impact of Haemophilus influenzae type B conjugate vaccines in the United States and Canada. Pediatr Infect Dis J. 1998;17(9 suppl):S132-S136.

9. Shah RK, Roberson DW, Jones DT. Epiglottitis in the Hemophilus influenzae type b vaccine era: changing trends. Laryngoscope. 2004;114(3):
557-560.

10. Mayo-Smith MF, Spinale JW, Donskey CJ, Yukawa M, Li RH, Schiffman FJ. Acute epiglottitis: an 18-year experience in Rhode Island. Chest. 1995;108(6):1640-1647.

11. Schuller DE, Birck HG. The safety of intubation in croup and epiglottitis: an eight-year follow-up.
Laryngoscope. 1975;85(1):33-46.

12. Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008;46(2):
186-192.